BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
229
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

- In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies
- The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell
- The global market for autoimmune disorder therapies is expected to reach $90.7 billion by 2024; The global market for infectious disease therapeutics is expected to reach $167 billion by 2030

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases – with a primary focus on diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma, and psoriasis.

The company is developing a pipeline of innovative nanosized antibody (NanoAb) therapies in collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), both in Germany. The NanoAb project’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was recently awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his seminal work describing protein transport within the cell (https://nnw.fm/wdiUf ).

“I wish to offer my sincere congratulations to Dirk on being awarded the inaugural WLA Prize in Life Sciences. The award signals recognition and appreciation of his important research achievements and deep scientific acumen. His expertise extends to the unique and innovative NanoAb candidates being developed under our collaboration,” CEO Amir Reichman said, on behalf of the BiondVax team. “We look forward to forging ahead together with Dirk, Matthias, and their teams as we strive to bring a pipeline of NanoAb therapies that exhibit significant competitive advantages for conditions underserved by currently approved therapeutics.”

BiondVax’s NanoAbs, also known as VHH-antibodies or nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production.

BiondVax currently has an exclusive worldwide license for the development and commercialization of an inhaled COVID-19 NanoAb therapy, expected to enter clinical trials in 2023. BiondVax, Max Planck, and UMG also signed a broad five-year research collaboration in March 2022 under which BiondVax has exclusive options for similar worldwide licenses for NanoAbs addressing large market disorders currently underserved by approved therapeutic antibodies. The agreement covers the discovery, development, and commercialization of NanoAbs therapies for indications such as asthma, psoriasis, macular degeneration, and psoriatic arthritis.

The global market for autoimmune disorder therapies such as asthma, arthritis and psoriasis is expected to grow from $53.2 billion in 2019 to $90.7 billion by 2024, growing at a CAGR of 11.2% over the forecast period (https://nnw.fm/d62sl ). The global infectious disease therapeutics market is expected to grow from an estimated $119.87 billion in 2022 to $167 billion in 2030, growing at a CAGR of 4.23% (https://nnw.fm/0CeuK ). The primary factors driving key growth in these markets are the increased number of cases suffering from infectious and autoimmune diseases and the growing senior population.

The company is in a unique position to advance NanoAb innovation from R&D through commercialization and offers a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb. Since being founded BiondVax has executed eight clinical trials including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate. The company built, owns, and operates a 20,000-square-foot state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities, and offices.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links

BVXV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 84

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 22

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 165

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 85

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 167

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 88

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading

Top 5 Most Recently Viewed Articles

Oncotelic Therapeutics 2024 Financial Year Report Summary

Updated Category News Views 219

Oncotelic Therapeutics: A Year of Growth and Development Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a pioneer in innovative treatments for rare diseases, is celebrating a successful fiscal year 2024. The company, known for its work in serious conditions such as pancreatic cancer and pediatric tumors, has reported significant advancements in its clinical and operational...

Continue Reading
OPC Energy Financial Results Coming: What Should You Know?

Updated Category News Views 262

Eyes on OPC Energy's Upcoming Financial Reveal Don’t sleep on March 12, 2026, folks. That’s the day OPC Energy Ltd. (TASE: OPCE) is ready to spill the beans on their fourth quarter and full year financial results for 2025. This isn't just another run-of-the-mill earnings call; it’s a pivotal moment that could set the stage for the company’s future in the energy...

Continue Reading
Zettabyte Appoints Sam Lawn as CFO to Advance AI Solutions

Updated Category News Views 219

Sam Lawn Takes Charge as Global Chief Financial Officer at Zettabyte PALO ALTO and TAIPEI — Zettabyte, an innovative leader in AI solutions with a focus on GPU infrastructure, has officially appointed Sam Lawn as the Global Chief Financial Officer, effective immediately. With this strategic move, Zettabyte aims to bolster its financial leadership and operational...

Continue Reading
AI Workforce Readiness Gap Splits C-Suite, Says Survey

Updated Category News Views 27

CHROs Sound Alarm on AI Readiness Here's the skinny: There's a growing split in the boardroom about rushing headlong into AI. While loads of execs are chomping at the bit—believing AI's about to boost everything from bottom lines to top lines like nobody's business—CHROs aren't so sold that their teams can handle the fast-paced AI implementation. They're seeing the...

Continue Reading
Tejon Ranch Co. Delivers Positive Results in Q3 2025

Updated Category News Views 183

Tejon Ranch Co.: A Review of Q3 2025 Performance Tejon Ranch Co., a prominent diversified real estate development and agribusiness company, has recently reported its financial performance for the third quarter of 2025. The company showcased a notable turnaround from the previous year, presenting a story of resilience and strategic management. Financial Highlights of the...

Continue Reading